Kolkata: The Kolkata Gynaecological Oncology Trials and Translational Research Group received ICMR funding for the clinical trial of a PARP inhibitor, a costly anti-cancer drug for targeted therapy involving mutations in the BRCA gene. The clinical trial will involve 350 patients suffering from ovarian cancer, the second leading cancer among women.Launched on Friday at the 8th annual meet organised by...